key: cord-1037036-klvct099 authors: Giot, Matthieu; Robert, Thomas; Brunet, Philippe; Resseguier, Noémie; Lano, Guillaume title: Vaccination against COVID-19 in a hemodialysis center: what is the risk of bleeding complications? date: 2021-03-15 journal: Clin Kidney J DOI: 10.1093/ckj/sfab059 sha: 231ede2e4f03d0ba63a2305435dfbe4a2c5d09d4 doc_id: 1037036 cord_uid: klvct099 nan Correspondence to: Guillaume Lano; E-mail: guillaume.lano@ap-hm.fr The coronavirus disease 2019 (COVID-19) has become pandemic all around the World since its beginning in Wuhan in December 2019. Dialysis patients have a 20-30% risk of death in case of COVID-19 (1) (2) (3) . Recently, Comirnaty Vaccine (BNT162b2; BioNTech and Pfizer) have been developed and approved in Europe (4) . To protect dialysis patients from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), international guidelines recommend to vaccine dialysis patients (5, 6) . Dialysis patients have higher bleeding risk compared to the general population due to their uremic status (7) and the frequent use of oral anticoagulant (OAC) (8) and/or antiplatelet agent (9) . This bleeding risk could be further increased during the dialysis session due to the anticoagulation of extra corporeal circuit. The intramuscular vaccination in dialysis patients need a safety evaluation. We performed vaccination on February 10 th and 11 th 2021 at every patients which gave their written consent in our hemodialysis centers. We analyzed the bleeding complications after the first dose of Comirnaty Vaccine in the deltoid muscle in a prospective manner. Inclusion criteria were hemodialysis patients who accepted and received vaccination the 10 th and 11 th February 2021. Exclusion criteria were age < 18 years, active or recent COVID in the 3 months before. Vaccination was done with the Comirnaty Vaccine in deltoid muscle on the contralateral arm of arterioveinous fistula when present (see Supplemental method). Ninety dialysis patients were vaccinated against COVID-19. 2 (2.2%) patients had the injection before the dialysis session, 27 (30%) in the two first hours of dialysis and 61 (67.8%) in the two last hours of dialysis. Timing of vaccination was not associated with bleeding complications (see Supplemental Figure S1 ). Twenty-three (25.5%) patients were treated with OAC. Among them, 2 patients with apixaban jumped the dose the day before and the vaccine day and 21 patients used vitamin K antagonists (VKA). 5 (5.6%) patients continued VKA treatment for the following reasons: cardiac mechanic valve (n=2), antiphospholipid syndrome (n=2), recent diagnostic of deep venous thrombosis (n=1). For the 16 remaining patients, VKA were managed at the physician's discretion. Eight patients jumped the doses the session before and the vaccine day, 4 patients jumped the dose only at the previous session before vaccine day and 4 patients jumped the dose only the vaccine day. The International Normalized Ratio (INR) was lower than 3.2 for all the patients, the vaccine day. 79 patients received unfractionated heparin during the dialysis sessions and 2 patients with history of heparin-induced thrombocytopenia received danaparoid sodium. The 9 remaining patients did not receive anticoagulation during the dialysis session for the following reasons: 2 because OAC is usually sufficient to performed a 4 hours dialysis session and 7 had anticoagulation contraindication (2 with cholesterol embolism disease and 5 with high bleeding risk). Injection site was the contralateral shoulder at the vascular access. Age, history of COVID-19, use of antiplatelet agent, presence of thrombocytopenia and heparin dose did not differ according to anticoagulation status (see Supplemental Table 1 ). History of bleeding did not differ in OAC group compared to no OAC group (60.9±10% vs 40±6.1%respectively;p=0.09). No complications have been reported the vaccine day. At the next dialysis session 48 hours after the vaccine day , bleeding complications occurred in 6 (6.7%) patients with five (5.6%) ecchymosis and one patient had both ecchymosis and deep hematoma < 1 cm. OAC was not associated with bleeding complications (8.7±2.9% in OAC vs 6.0 ±2.4% in non-OAC group,p=0.64) (Figure 1A) . INR > 2 the vaccine day was not associated with bleeding complications (20.0%±21.0% with INR>2 vs 6.7 ± 6.5% with INR <2, p=0.39) ( Figure 1B) . Use of anticoagulant during the dialysis session was not statistically associated with bleeding complications (7.6±3.0% vs 0%, p = 0.34) (Figure 1C) . Use of antiplatelet agent or OAC alone, or both antiplatelet agent and OAC were not associated with bleeding complications compared with neither antiplatelet nor OAC ( Figure 1D) . The non-bleeding complications were as follow: mild-tomoderate pain at the injection site (n=32;35.6%) with one (1.1%) episode of redness and swelling; and systemic events: asthenia (n=13; 14.4%), headache (n=2; 2.2%) and flu syndrome with or without fever (n=11; 12.2%)(see Supplemental Table 2 ). Interestingly, history of COVID-19 was associated with fever compared to no medical history of COVID-19 (18.2±12% vs 2.5±1.8% respectively,p=0.02). OAC treatment was associated with less flu syndrome (16.4±4.6% vs 0%,p=0.04) (see Supplemental Table 2 ). Previous studies (10, 11) showed in general population the safety of intramuscular vaccine in patients receiving oral anticoagulation. In our study, only six minor bleedings complications occurred. OAC or heparin use were not associated a significant risk of bleeding complications. Compared to the general population (4), dialysis patients may have less local and systemic events. To ascertain that the vaccine is safe in the dialysis population under anticoagulation treatment, the number of subjects a posteriori to demonstrate the non-inferiority compared to the general population (4) is estimated at 23944 under the following hypotheses: (i) a rate of serious adverse events in the general population of 1.1%, (ii) a non-inferiority margin of 0.2%, (iii) a one-sided alpha risk at 2.5%, and (iv) a power of 80% (12) (13) (14) . The number of subjects needed makes this study difficult to perform. However, vaccination seems safe in our cohort, and the expected benefits far outweigh the observed risks. To our knowledge, we are the first to study the safety of intramuscular vaccine concerning bleeding complications in chronic dialysis patients with OAC and/or heparin during dialysis session. In conclusion, vaccination against COVID 19 during the dialysis session appears to be safe, particularly regarding bleeding risk, even in patients under OAC. The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request. The authors declare that they have no competing interests. No funding was obtained for this study. Risk factors for severity of COVID-19 in chronic dialysis patients from a multicentre French cohort Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine Chronic kidney disease is a key risk factor for severe COVID-19: a call to action by the ERA-EDTA The urgent need to vaccinate dialysis patients against severe acute respiratory syndrome coronavirus 2: a call to action Haemostasis in chronic kidney disease Anticoagulation in Concomitant Chronic Kidney Disease and Atrial Fibrillation: JACC Review Topic of the Week Prevalence of atheromatous and non-atheromatous cardiovascular disease by age in chronic kidney disease Influenza vaccination and vitamin K antagonist treatment: a placebo-controlled, randomized, doubleblind crossover study Safety of intramuscular influenza vaccine in patients receiving oral anticoagulation therapy: a single blinded multicentre randomized controlled clinical trial Equivalence Trials. In: Armitage P, Colton T, éditeurs. Encyclopedia of Biostatistics Sample size calculations in clinical research